Use of Research Funding. Company shall apply any Research funding it receives from Merck under this Agreement solely to carry out its Research Program activities in accordance with Schedule 2.1, as may be revised from time to time pursuant to Section 2.1, and the terms and conditions of this Agreement. Apart from the foregoing, each Party shall be responsible for its own cost and expense in carrying out its activities under the Research Program.
Use of Research Funding. Ablynx shall apply the research funding it receives from Merck under this Agreement solely to carry out its activities in respect of the Research Programs in accordance with the applicable Work Plans and the terms and conditions of this Agreement, and for no other purpose.
Use of Research Funding. AVEO shall apply the research funding it receives from MERCK under this Agreement to carry out its Research Program activities in accordance with Schedule 2.1 and the terms and conditions of this Agreement.
Use of Research Funding. The Company shall apply the research funding it receives from TSF under this Agreement for the sole purpose of conducting the Sponsored Research. TSF acknowledges and agrees that the cost of the Sponsored Research will exceed the amount set forth in the Budget and that there is no express or implied commitment by the Company, any affiliate of the Company or any other party to fund, commit, contribute or expend any of their financial or other resources to advance the Sponsored Research, to complete the Sponsored Research or to reach any particular stage or point of development with respect to the Sponsored Research.
Use of Research Funding. Ambrx shall apply the research funding it receives from Agensys under this Agreement to carry out its Research Program activities in accordance with the Research Plan and the terms and conditions of this Agreement.
Use of Research Funding. NS shall apply the research funding it receives from CTI under this Research Agreement to conduct the research set forth in the Research Plan.
Use of Research Funding. MTI shall apply all funding it receives from Sankyo under this Agreement (other than milestone payments payable by Sankyo to MTI pursuant to Section 7.3) for the sole purpose of discovering, identifying, studying, improving and testing Research Compounds in accordance with the Research Program (including overhead expenses related thereto) set forth on Appendix A hereto, and amended from time to time by the parties, with the goal of identifying candidate compounds for designation as Recommended Compounds. All milestone payments paid by Sankyo to MTI pursuant to Section 7.3 shall be used by MTI for working capital purposes. In each of the first two Research Years during the term of the Research Program, MTI shall allocate an average of approximately [***] full time equivalent researchers and staff to perform its obligations under the Research Program. In the third Research Year during the term of the Research Program, MTI shall allocate an average of [***] full time equivalent researchers and staff to perform its obligations under the Research Program [***]. MTI's staffing obligations during the term of the Research Program shall be subject to adjustment at the recommendation of the Steering Committee. Sankyo acknowledges that MTI's allocation of full time equivalent researchers and staff to perform its obligations under the Research Program during the period commencing on the Effective Date and ending on the date hereof has been acceptable. MTI shall continue to fulfill its obligations under this Section 3.1.2 by allocating full time equivalent researchers and staff in a manner which is consistent with its past practices.
Use of Research Funding. Osiris shall apply the research funding it receives from Novartis under this Agreement for the purpose of identification and pre-clinical development of Products, applying the number of Full Time Equivalents (FTEs) specified in Schedule C. At least 25% (twenty five percent) of the FTEs specified for each Area shall be assigned to the Research Program in that Area within one (1) month from the Start-up Date, at least 60% (sixty percent) within two (2) months from the Start-up Date, and at least 100% (one hundred percent) within three (3) months from the Start-up Date, whereby any under-allocation of FTEs during this initial three (3) month period shall be made good by the first anniversary of the Start-up Date. It is also understood and agreed that an FTE may be provided by one, two or more persons. For each Area, a senior scientist, mutually acceptable to both parties, shall be appointed as Program Leader for the Research Program in that Area.
Use of Research Funding. ARRIS shall apply the research funding it receives from MERCK under this Agreement in accordance with the Research Program attached hereto as Attachment 2.1, as such may be amended from time to time upon the mutual written agreement of authorized representatives of the parties.
Use of Research Funding. Ambrx shall apply the research funding it receives from Merck under this Agreement to carry out its Research Program activities in accordance with the applicable Research Plan and the terms and conditions of this Agreement.
